Perioperative systemic haemostatic agents

British Journal of Anaesthesia

Volumn 93, Issue 6, 2004, Pages 842-858

  Mahdy, A M ^a   Webster, N R ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Blood, factor VIIa; Blood, haemostasis; Blood, loss; Polypeptides, aprotinin

Indexed keywords

AMINOCAPROIC ACID; ANESTHETIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; ANTITHROMBIN; APROTININ; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9A; CORTICOSTEROID; DESMOPRESSIN ACETATE; HEMOSTATIC AGENT; HEPARIN; KALLIKREIN; LYSINE DERIVATIVE; NAFAMSTAT; PLACEBO; PLASMIN; PLASMINOGEN; PROTEIN C; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; ANEMIA; ANESTHESIST; ARTERY THROMBOSIS; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; BLOOD TRANSFUSION; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; FIBRINOLYSIS; FLUSHING; GENE ACTIVATION; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEART SURGERY; HEMODYNAMICS; HEMOPHILIA A; HUMAN; HYPONATREMIA; HYPOTENSION; HYPOVOLEMIA; LUNG EMBOLISM; MORBIDITY; MUSCLE WEAKNESS; MYOPATHY; NAUSEA; NEPHROTOXICITY; OXYGEN TRANSPORT; PATIENT POSITIONING; PERIOPERATIVE PERIOD; PHYSICIAN ATTITUDE; PREMATURE LABOR; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROGRADE EJACULATION; REVIEW; RHABDOMYOLYSIS; SEIZURE; SHOCK; SUBARACHNOID HEMORRHAGE; SURGICAL MORTALITY; SURGICAL TECHNIQUE; THROMBOEMBOLISM; THROMBOSIS; VOMITING; WATER RETENTION;

EID: 9744269881     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeh227     Document Type: Review

References (159)

1. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.J Thorac Cardiovasc Surg 1998; 116: 716-30
2. Al-Douri M, Shafi T, Al-Khudairi D, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11: S121-7
3. Bedirhan MA,Turna A, Yagan N, Tasci O. Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. Eur J Cardiothorac Surg 2001; 20: 1122-7
4. Benoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand 2001; 72: 442-8
5. Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand 2000; 71: 250-4
6. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-72
7. Blackwell KE, Ross DA, Kapur P. Propofol for maintenance of general anesthesia: a technique to limit blood loss during endoscopic sinus surgery. Am J Otolaryngol 1993; 14: 262-6
8. Bohrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 1990; 4: 222-5
9. Boylan JF, Klinck JR, Sandler AN, et al. Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 1996; 85: 1043-8
10. Brown RS, Thwaites BK, Mongan PD. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial. Anesth Analg 1997; 85: 963-70
11. Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Lond) 1998; 94: 505-9
12. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F. Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 1998; 88: 50-7
13. Casati V, Bellotti F, Gerli C, et al. Tranexamic acid administration after cardiac surgery: a prospective, randomized, double-blind, placebo-controlled study. Anesthesiology 2001; 94 8-14
14. Casati V, Gerli C, Franco A, et al. Tranexamic acid in off-pump coronary surgery: a preliminary, randomized, double-blind, placebo-controlled study. Ann Thorac Surg 2001; 72: 470-5
15. Casati V, Guzzon D, Oppizzi M, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg 2000; 120: 520-7
16. Casati V, Sandrelli L, Speziali G, Calori G, Grasso MA, Spagnolo S. Hemostatic effects of tranexamic acid in elective thoracic aortic surgery: a prospective, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 2002; 123: 1084-91
17. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery - a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995; 74: 1064-70
18. Chuansumrit A, Treepongkaruna S, Phuapradit P. Combined fresh frozen plasma with recombinant factor VIIa in restoring hemostasis for invasive procedures in children with liver diseases. Thromb Haemost 2001; 85: 748-9
19. Clagett GP, Valentine RJ, Myers SI, Chervu A, Heller J. Does desmopressin improve hemostasis and reduce blood loss from aortic surgery? A randomized, double-blind study. J Vasc Surg 1995; 22 223-9
20. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91: 29-34
21. Despotis GJ, Levine V,Saleem R, Spitznagel E, Joist JH. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomized controlled trial. Lancet 1999; 354: 106-10
22. Dewachter P, Mouton C, Masson C, Gueant JL, Haberer JP. Anaphylactic reaction to aprotinin during cardiac surgery. Anaesthesia 1993; 48: 1110-1
23. Diefenbach C, Abel M, Limpers B, et al. Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 1995; 80: 830-1
24. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995; 83 679-89
25. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred and forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997; 113: 194-201
26. Dietrich W, Spath P, Zuhlsdorf M, et al. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to anti-aprotinin immunoglobulin G and E antibodies. Anesthesiology 2001; 95: 64-71
27. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993; 7: 425-30
28. Doughty HA, Northeast A, Sklair L, et al. The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery. Blood Coagul Fibrinolysis 1995; 6: 125-8
29. Dryden PJ, O'Connor JP, Jamieson WR, et al. Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery. Can J Anaesth 1997; 44: 934-41
30. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005-32
31. Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Effect of progressive haemodilution with hydroxyethyl starch,gelatin and albumin on blood coagulation. Br J Anaesth 1997; 78: 684-9
32. Ekback G, Axelsson K, Ryttberg L, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000; 91: 1124-30
33. Englberger L, Markart P, Eckstein FS, Immer FF, Berdat PA, Carrel TP. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur J Cardiothorac Surg 2002; 22: 545-51
34. Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost 2001; 86: 942-4
35. Feindt PR, Walcher S, Volkmer I, et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995; 60: 1076-80
36. Findlay JY, Rettke SR, Ereth MH, Plevak DJ, Krom RA, Kufner RP. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. Liver Transpl 2001; 7: 802-7
37. Flordal PA, Ljungstrom KG, Ekman B, Neander G. Effects of desmopressin on blood loss in hip arthroplasty. Controlled study in 50 patients. Acta Orthop Scand 1992; 63: 381-5
38. Forestier F, Coiffic A, Mouton C, Ekouevi D, Chene G, Janvier G. Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant? Br J Anaesth 2002; 89: 715-21
39. Franck M, Sladen RN. Drugs to prevent and reverse anticoagulation. Anesthesiol Clin North America 1999; 17: 799-811
40. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58: 1580-8
41. Frenette L, Cox J, McArdle P, Eckhoff D, Bynon S. Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. Anesth Analg 1998; 86: 1183-6
42. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003; 361: 201-5
43. Friederich PW, Wever PC, Briet E. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66: 292-4
44. Fujii S, Hitomi Y. New synthetic inhibitors of CIr, C I esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661: 342-5
45. Gilliland HE, Armstrong MA, Uprichard S, Clarke G, McMurray TJ. The effect of aprotinin on interleukin-8 concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system. Anaesthesia 1999; 54: 427-33
46. Gombotz H, Metzler H, List WF. Methods of reduction of perioperative bleeding. Br J Anaesth 1998; 81 (Suppl. 1): 62-66
47. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998; 66: 747-53
48. Guay J, Reinberg C, Rivard GE, Poitras B, Mathews S, David M. DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 1990; 37: S14
49. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991; 51: 936-41
50. Harig F, Feyrer R, Mahmoud FO, Blum U, von der Emde J. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin. Thorac Cardiovasc Surg 1999; 47: 111-8
51. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807-10
52. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-7
53. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997; 114: 261-9
54. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193
55. Hendriks HG, Meijer K, deWolf JT. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001; 71: 402-5
56. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-9
57. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001: CD001886
58. Hiippala ST, Strid LJ, Wennerstrand MI, et al. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997; 84 839-44
59. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658-62
60. Hill GE, Robbins RA. Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Anesth Analg 1997; 84: 1198-202
61. Hoffmann H, Siebeck M, Thetter O, Jochum M, Fritz H. Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv Exp Med Biol 1989; 247B: 35-42
62. Horrow JC. Desmopressin and antifibrinolytics. Int Anesthesiol Clin 1990; 28: 230-6
63. Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia 1998; 4: 689-96
64. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K. Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth 1999; 83: 596-601
65. Jensen LS, Grunnet N, Hanberg-Sorensen F, Jorgensen J. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35: 719-22
66. Kang Y, Lewis JH, Navalgund A, et al. Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. Anesthesiology 1987; 66: 766-73
67. Karnezis TA, Stulberg SD, Wixson RL, Reilly P. The hemostatic effects of desmopressin on patients who had total joint arthroplasty. A double-blind randomized trial. J Bone Joint Surg Am 1994; 76: 1545-50
68. Kaspar M, Ramsay MA, Nguyen AT, Cogswell M, Hurst G, Ramsay KJ. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 1997; 85: 281-5
69. Kawasuji M, Ueyama K, Sakakibara N, et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 1205-9
70. Kesten S, de Hoyas A, Chaparro C, Westney G, Winton T, Maurer JR. Aprotinin reduces blood loss in lung transplant recipients. Ann Thorac Surg 1995; 59: 877-9
71. Kida H, Nishikawa N, Matsunami K, Katsuyama R, Kawahito M. The effect of epidural anesthesia on reducing blood loss during upper abdominal surgery. Masui 1999; 48: 265-70
72. Kobrinsky NL, Letts RM, Patel LR, et al. 1-Desamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomized, double-blinded, controlled trial. Ann Intern Med 1987; 107: 446-50
73. Kovesi T, Royston D. Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 2003; 84: 2-10
74. Kristensen J, Killander A, Hippe E. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26: 1159-64
75. Kumarasinghe N, Harpin R, Stewart AW. Blood loss during suction termination of pregnancy with two different anaesthetic techniques. Anaesth Intensive Care 1997; 25: 48-50
76. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 1996; 334: 1209-15
77. Kyriss T, Wurst H, Friedel G, Jaki R, Toomes H. Reduced blood loss by aprotinin in thoracic surgical operations associated with high risk of bleeding. A placebo-controlled, randomized phase IV study. Eur J Cardiothorac Surg 2001; 20: 38-41
78. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Perioperative Transfusion (ISPOT) Investigators. Anesth Analg 1997; 85: 1258-67
79. Lavee J, Savion N, Smolinsky A, Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1992; 53: 477-81
80. Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996; 62: 1659-67
81. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-51
82. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995; 59: 132-6
83. Lentschener C, Cottin P, Bouaziz H, et al. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 1999; 89: 590-7
84. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effecton FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58 1033-6
85. Lethagen S, Rugarn P, Bergqvist D. Blood loss and safety with desmopressin or placebo during aorto-iliac graft surgery. Eur J Vasc Surg 1991; 5: 173-8
86. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354: 1940-7
87. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92: 2236-44
88. Litwack RS, Horrow JC. Lethal thrombosis during coronary artery bypass graft surgery. Anesthesiology 1987; 67: 134-6
89. Livio M, Mannucci PM, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315: 731-5
90. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245-53
91. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55
92. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93
93. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-8
94. McCall RE, Bilderback KK. Use of intravenous Premarin to decrease postoperative blood loss after pediatric scoliosis surgery. Spine 1997; 22: 1394-7
95. Miller RA, May MW, Hendry WF, Whitfield HN, Wickham JE. The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br J Urol 1980; 52: 26-8
96. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2 1227-9
97. Molenaar IQ, Begliomini B, Grazi GL, Ringers J, Terpstra OT, Porte RJ. The effect of aprotinin on renal function in orthotopic liver transplantation. Transplantation 2001; 71: 247-52
98. Molenaar IQ, Begliomini B, Martinelli G, Putter H, Terpstra OT, Porte RJ. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 2001; 94: 433-8
99. Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization. Anesth Analg 1998; 87: 258-65
100. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46
101. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7
102. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001; 114: 174-6
103. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 1999; 99: 81-9
104. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993; 88: 11432-6
105. Murkin JM. Attenuation of neurologic injury during cardiac surgery. Ann Thorac Surg 2001; 72: S1838-44
106. Murkin JM, Haig GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am 2000; 82: 675-84
107. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg 1995; 80: 343-8
108. Neuhaus P, Bechstein WO, Lefebre B, Blumhardt G, Slama K. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet 1989; 2: 924-5
109. Orchard MA, Goodchild CS, Prentice CR, et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-41
110. Palmer JD, Francis JL, Pickard JD, Iannotti F. The efficacy and safety of aprotinin for hemostasis during intracranial surgery.J Neurosurg 2003; 98: 1208-16
111. Use of NovoSeven in patients undergoing orthotopic liver transplantation. In: Proceedings of the 6th NovoNordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders, 2001; Copenhagen, 2001
112. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999; 94: 3951-3
113. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62: 2193-211
114. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomized double-blind study. EMSALT Study Group. Lancet 2000; 355: 1303-9
115. Prendergast TW, Furukawa S, Beyer AJ 3rd, Eisen HJ, McClurken JB, Jeevanandam V. Defining the role of aprotinin in heart transplantation. Ann Thorac Surg 1996; 62: 670-4
116. Product monograph. Novo Seven, NovoNovdisk, Copenhagen, 2001
117. Rahman A, Ustunda B, Burma O, Ozercan IH, Cekirdekci A, Bayar MK. Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? Eur J Cardiothorac Surg 2000; 18: 583-8
118. Rao AK, Ghosh S, Sun L. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects: a double-blind placebo-controlled trial. Thromb Haemost 1995; 74: 1071-8
119. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 1997; 78: 1021-6
120. Reid RW, Zimmerman AA, Laussen PC, Mayer JE, Gorlin JB, Burrows FA. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg 1997; 84: 990-6
121. Revesz T, Arets B, Bierings M. Recombinant factor VIIa in severe uremic bleeding [letter]. Thromb Haemost 1998; 80: 353
122. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9 (Suppl. I): S115-8
123. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100
124. Royston D. Intraoperative coronary thrombosis: can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994; 8: 137-41
125. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-91
126. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Aprotinin (Trasylol) reduces bleeding after open heart surgery in patients taking aspirin and those with renal failure. Anesthesiology 1989; 71 (Suppl.): A6
127. Ruttmann TG, James MF, Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 1998; 80: 612-6
128. Sagripanti A, Sarteschi LM, Camici M, Puccetti S, Capri A. Nontransfusional haemostatic agents in the management of bleeding disorders. Intern Med 2001; 9: 10-18
129. Samama CM, Langeron O, Rosencher N, et al. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth Analg 2002; 95: 287-93
130. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86 954-8
131. Santamaria A, Mateo J, Oliver A, et al. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. Haematologica 2000; 85: 1277-84
132. Sato T, Tanaka K, Kondo C, et al. Nafamostat mesilate administration during cardiopulmonary bypass decreases postoperative bleeding after cardiac surgery. ASAIO Trans 1991; 37: M194-5
133. Scheule AM, Jurmann MJ, Wendel HP, Haberle L, Eckstein FS, Ziemer G. Anaphylactic shock after aprotinin reexposure: time course of aprotinin-specific antibodies. Ann Thorac Surg 1997; 63: 242-4
134. Schmartz D, Tabardel Y, Preiser JC, et al. Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients? J Thorac Cardiovasc Surg 2003; 125: 184-90
135. Schneeberger AG, Schulz RF, Ganz R. Blood loss in total hip arthroplasty. Lateral position combined with preservation of the capsule versus supine position combined with capsulectomy. Arch Orthop Trauma Surg 1998; 117: 47-9
136. Schott U, Sollen C, Axelsson K, Rugarn P, Allvin I. Desmopressin acetate does not reduce blood loss during total hip replacement in patients receiving dextran. Acta Anaesthesiol Scand 1995; 39: 592-8
137. Schweizer A, Hohn L, Morel DR, Kalangos A, Licker M. Aprotinin does not impair renal haemodynamics and function after cardiac surgery. Br J Anaesth 2000; 84: 16-22
138. Seymour BD, Rubinger M. Rhabdomyolysis induced by epsilon-aminocaproic acid. Ann Pharmacother 1997; 31: 56-58
139. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8
140. Shemin D, Elnour M, Amarantes B, Abuelo JG, Chazan JA. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990; 89: 436-40
141. Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994; 37: 33-6
142. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997; 96: 569-74
143. Shimada M, Matsumata T, Shirabe K, Kamakura T, Taketomi A, Sugimachi K. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection. J Am Coll Surg 1994; 178: 498-502
144. Smith CR. Management of bleeding complications in redo cardiac operations. Ann Thorac Surg 1998; 65: S2-8
145. Smith MP, Ludlam CA, Collins PW, et al. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 2001; 86: 949-53
146. Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 2000; 93: 242-55
147. Swart MJ, Gordon PC, Hayse-Gregson PB, et al. High-dose aprotinin in cardiac surgery-a prospective, randomized study. Anaesth Intensive Care 1994; 22: 529-33
148. Tanaka K, Kondo C, Takagi K, et al. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. Asaio J 1993; 39: M545-9
149. Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br 2001; 83: 702-5
150. Taylor KM. Improved outcome for seriously ill open heart surgery patients: focus on reoperation and endocarditis. J Heart Lung Transplant 1993; 12: S14-8
151. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovosc Surg 1990; 99: 788-96
152. Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand 2002; 46 1206-11
153. Vermeulen M, Lindsay KW, Murray GD. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311: 432-7
154. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61
155. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9
156. Wahba A, Black G, Koksch M, et al. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb Haemost 1996; 75: 844-8
157. Wells PS. Safetyand efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002; 9: 377-88
158. Welty-Wolf KE, Carraway MS, Miller DS. Tissue factor blockade in experimental acute lung injury. In: Programme and abstracts from the 6th Novo Nordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders, 2001. Copenhagen, 2001
159. Wendel HP, Heller W, Michel J, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109: 1164-72